Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

1998243 citationsJournal Article

Authors

B.A. Tjoa

S.J. Simmons · Northwest Hospital

Victoria Bowes · Northwest Hospital

Haakon Ragde · Northwest Hospital

M. Rogers · Northwest Hospital

A. Elgamal · Northwest Hospital

Gerald M. Kenny · Northwest Hospital

Abstract

The responses observed in the phase I and II clinical trials were significant and of long duration. The partial-responder group included patients who continued to respond from phase I, as well as those who started to respond during the phase II trial.

Topics & Keywords

Immunotherapy and Immune Responses vaccines and immunoinformatics approaches RNA Interference and Gene Delivery

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Prostate

Volume 36, Issue 1, pp. 39-44

DOI: 10.1002/(sici)1097-0045(19980615)36:1<39::aid-pros6>3.0.co;2-6

Field-Weighted Citation Impact: 8.55